ALK and non-small cell lung carcinoma: Whereas crizotinib therapy provides durable responses lasting about a year, ceritinib, alectinib, and brigatinib are indicated as second-line treatment after a patient’s ALK-positive NSCLC has developed resistance to crizotinib.